NCT03402464 - Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

June 1, 2019

Study Completion Date

September 20, 2020

Conditions

EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma

Interventions

DRUG

Icotinib combined dihydroaremisinin

Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing